← SynDRA
GSK-256066
SynDRA canonical compound SYN0020245 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
| Primary target(s) | PDE4A | PDE4B | PDE4C | PDE4D |
| Mechanism of action | phosphodiesterase inhibitor |
All known targets
Mechanisms of action (all sources)
- PDE4A INHIBITOR
- Phosphodiesterase 4 inhibitor
- PDE4D INHIBITOR
- PDE4B INHIBITOR
- PDE4C INHIBITOR
- phosphodiesterase inhibitor
Cross-references
Synonyms
- GSK256066
- O66
- GSK 256066
- 6-[[3-[(DIMETHYLAMINO)CARBONYL]PHENYL]SULFONYL]-4-[(3-METHOXYPHENYL)AMINO]-8-METHYL-3-QUINOLINECARBOXAMIDE
- 6-(3-(dimethylcarbamoyl)phenylsulfonyl)-4-(3-methoxyphenylamino)-8-methylquinoline-3-carboxamide
- GSK256066 free base
- 6-[3-(Dimethylcarbamoyl)phenyl]sulfonyl-4-(3-methoxyanilino)-8-methylquinoline-3-carboxamide
- 2D6GK059SR
- CHEMBL570015
- 801312-28-7 (free base)
- 3-Quinolinecarboxamide, 6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methyl-
- 6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide
- UNII-2D6GK059SR
- 3gwt
- 6-{[3-(dimethylcarbamoyl)phenyl]sulfonyl}-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide
- MLS006011116
- SCHEMBL1148649
- DTXSID30230090
- HMS3656P03
- BCP02627
- EX-A2066
- ZINC6717510
- BDBM50415001
- MFCD18206923
- s2620
- AKOS025405260
- BCP9000740
- CCG-269844
- CS-0349
- DB12137
- SB19575
- NCGC00346620-01
- NCGC00346620-06
- NCGC00346620-08
- AC-32928
- HY-10469
- SMR004702897
- SW219741-1
Look up GSK-256066 in the interactive SynDRA portal →